This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a phase I trial of SAHA administered by mouth in increasing dose in combination with bortezomib given intravenously twice weekly (days 1 and 4,8 and 11). The cycles are repeated every 3 weeks. The study will establish the safe dose that can be given for this combination. At the beginning of the study 3 patients will be treated with a low dose of SAHA and Bortezomib. If this dose does not cause severe side effects it will gradually be increased as new patients take part in the study. Patients will take this combination of drugs for up to 8 cycles (24 weeks) on an outpatient basis. An 8 hour pharmacokinetic assessment will be done on day 4 of cycle 1 only.
Showing the most recent 10 out of 411 publications